Increased risk of varicella zoster virus infection in inflammatory bowel disease in an Asian population: A nationwide population-based cohort study

International Journal of Clinical Practice

Volumn 69, Issue 2, 2015, Pages 228-234

  Tsai, S Y ^a,b   Yang, T Y ^c,d   Lin, C L ^c,e   Tsai, Y H ^f,g   Kuo, C F ^a   Kao, C H ^c,h  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^g FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASIAN; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CROHN DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH INSURANCE; HEALTH PROGRAM; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; OBESITY; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TAIWAN; ULCERATIVE COLITIS; YOUNG ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHICKENPOX; COMPLICATION; INFLAMMATORY BOWEL DISEASES; RISK FACTOR; VARICELLA ZOSTER VIRUS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHICKENPOX; COHORT STUDIES; COMORBIDITY; FEMALE; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TAIWAN;

EID: 84921770514     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12508     Document Type: Article

References (35)

1. Heininger U, Seward JF,. Varicella. Lancet 2006; 368: 1365-76.
2. Singh S, Kumar N, Loftus EV Jr, et al. Neurologic complications in patients with inflammatory bowel disease: increasing relevance in the era of biologics. Inflamm Bowel Dis 2013; 19: 864-72.
3. Gilden D, Cohrs RJ, Mahalingam R, et al. Varicella zoster virus vasculopathies: diverse clinical manifestations, laboratory features, pathogenesis, and treatment. Lancet Neurol 2009; 8: 731-40.
4. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271-84.
5. Cohen JI,. Herpes zoster. N Engl J Med 2013; 369: 255-63.
6. de Jong MD, Weel JF, van Oers MH, et al. Molecular diagnosis of visceral herpes zoster. Lancet 2001; 357: 2101-2.
7. Arvin A,. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005; 352: 2266-7.
8. Jih JS, Chen YJ, Lin MW, et al. Epidemiological features and costs of herpes zoster in Taiwan: a national study 2000 to 2006. Acta Derm Venereol 2009; 89: 612-6.
9. Long MD, Martin C, Sandler RS, et al. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013; 37: 420-9.
10. Cheng TM,. Taiwan's National Health Insurance system: high value for the dollar. In:, Okma KGH, Crivelli L, eds. Six Countries, Six Reform Models: The Health Reform Experience of Israel, the Netherlands, New Zealand, Singapore, Switzerland and Taiwan. Hackensack, NJ: World Scientific, 2009: 71-204.
11. Wang CC, Lin CL, Chang YJ, et al. Herpes zoster infection associated with acute coronary syndrome: a population-based retrospective cohort study. Br J Dermatol 2014; 170 (5): p. 1122-9.
12. Meyer PA, Seward JF, Jumaan AO, et al. Varicella mortality: trends before vaccine licensure in the United States, 1970-1994. J Infect Dis 2000; 182: 383-90.
13. White RR, Lenhart G, Singhal PK, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics 2009; 27: 781-92.
14. Hambleton S, Gershon AA,. Preventing varicella-zoster disease. Clin Microbiol Rev 2005; 18: 70-80.
15. Targownik LE, Bernstein CN,. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol 2013; 108: 1835-42, quiz 43.
16. Lawrance IC, Radford-Smith GL, Bampton PA, et al. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol 2010; 25: 1732-8.
17. Joossens M, van Steen K, Branche J, et al. Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease. Inflamm Bowel Dis 2010; 16: 58-67.
18. Baron S, Turck D, Leplat C, et al. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 2005; 54: 357-63.
19. Baumgart DC, Carding SR,. Inflammatory bowel disease: cause and immunobiology. Lancet 2007; 369: 1627-40.
20. Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA 2012; 308: 43-9.
21. Cho JH,. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8: 458-66.
22. Geremia A, Biancheri P, Allan P, et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014; 13: 3-10.
23. Cho JH, Weaver CT,. The genetics of inflammatory bowel disease. Gastroenterology 2007; 133: 1327-39.
24. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-34.
25. Gupta G, Lautenbach E, Lewis JD,. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483-90.
26. Devroede GJ, Taylor WF, Sauer WG, et al. Cancer risk and life expectancy of children with ulcerative colitis. N Engl J Med 1971; 285: 17-21.
27. Fraser AG, Orchard TR, Jewell DP,. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9.
28. Dave M, Purohit T, Razonable R, et al. Opportunistic infections due to inflammatory bowel disease therapy. Inflamm Bowel Dis 2014; 20: 196-212.
29. Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 20-34.
30. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-44.
31. Sonnenberg A, McCarty DJ, Jacobsen SJ,. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology 1991; 100: 143-9.
32. Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis 2008; 197: 825-35.
33. Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine 2010; 28: 4204-9.
34. Hendriksz T, Malouf P, Foy JE,. Vaccines for measles, mumps, rubella, varicella, and herpes zoster: immunization guidelines for adults. J Am Osteopath Assoc 2011; 111: S10-2.
35. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States, 2013. J Midwifery Womens Health 2013; 58: 215-20.